Global Fibrotic Diseases Treatment Market - Industry Trends and Forecast to 2030

Description

List of Tables

The global fibrotic diseases treatment market is projected to register a substantial CAGR of 6.0%in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.

Market Segmentation:

Global Fibrotic Diseases Treatment Market, By Treatment (Medication, Organ Transplantation, Oxygen Therapy, Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Country (U.S., Canada, Mexico, Dominican Republic, Jamaica, Panama Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Taiwan Rest of Asia-Pacific, Brazil, Ecuador, Chile, Colombia, Venezuela, Argentina, Peru, Curacao, Paraguay, Uruguay, Trinidad And Tobago, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Bahrain Israel, Rest of the Middle East and Africa) Industry Trends and Forecast to 2030.

Some of the major factors contributing to the growth of the global fibrotic diseases treatment market are:

Rising prevalence of fibrotic diseases

Increase in the number of people smoking cigarettes

Market Players:

Some of the key market players in the global fibrotic diseases treatment market are listed below:

Genentech, Inc.

Boehringer Ingelheim International GmbH

AbbVie Inc.

Redx Pharma Plc

Bristol-Myers Squibb Company

BellBrook Labs

Enveda Biosciences

BioMX

Gilead Sciences, Inc.

KITHER BIOTECH S.R.L.

Verona Pharma plc

Alpine Immune Sciences

Intercept Pharmaceuticals, Inc.

Pharmaxis Ltd.

Teva Pharmaceutical Industries Ltd.

Sandoz International GmbH

Accord Healthcare

Camber Pharmaceuticals, Inc

1 INTRODUCTION 34

1.1 OBJECTIVES OF THE STUDY 34
1.2 MARKET DEFINITION 34
1.3 OVERVIEW OF THE GLOBAL FIBROTIC DISEASES TREATMENT MARKET 34
1.4 LIMITATIONS 36
1.5 MARKETS COVERED 36

2 MARKET SEGMENTATION 38

2.1 MARKETS COVERED 38
2.2 GEOGRAPHICAL SCOPE 39
2.3 YEARS CONSIDERED FOR THE STUDY 40
2.4 CURRENCY AND PRICING 40
2.5 DBMR TRIPOD DATA VALIDATION MODEL 41
2.6 MULTIVARIATE MODELLING 44
2.7 TREATMENT TYPE LIFELINE CURVE 44
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 45
2.9 DBMR MARKET POSITION GRID 46
2.10 MARKET END USER COVERAGE GRID 47
2.11 VENDOR SHARE ANALYSIS 48
2.12 SECONDARY SOURCES 49
2.13 ASSUMPTIONS 49

3 EXECUTIVE SUMMARY 50

4 PREMIUM INSIGHTS 52

4.1 PORTER'S 5 FORCES 55
4.2 PESTEL ANALYSIS 56

5 EPIDEMIOLOGY 57

5.1 INCIDENCE OF ALL BY GENDER 57
5.2 TREATMENT RATE 57
5.3 MORTALITY RATE 57
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 58
5.5 PATIENT TREATMENT SUCCESS RATE 58

6 INDUSTRY INSIGHTS 59

6.1 PATENT ANALYSIS 59
6.2 DRUG TREATMENT RATE BY MATURED MARKETS 59
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 59
6.4 KEY PRICING STRATEGIES 60
6.5 KEY PATIENT ENROLLMENT STRATEGIES 61

7 MERGERS AND ACQUISITIONS 63

7.1 LICENSING: 63
7.2 COMMERCIALIZATION AGREEMENTS 63

8 PIPELINE ANALYSIS 64

8.1 PHASE 1 64
8.2 PHASE 2 64
8.3 PHASE 3 64

9 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS 65

9.1 FDA APPROVALS 65
9.2 EMA APPROVALS 66

10 MARKET OVERVIEW 67

10.1 DRIVERS 69
- 10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES 69
- 10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES 69
- 10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES 70
10.2 RESTRAINTS 70
- 10.2.1 HIGH COST OF MEDICATION AND TREATMENTS 70
- 10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES 70
10.3 OPPORTUNITIES 71
- 10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 71
- 10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES 71
10.4 CHALLENGES 72
- 10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES. 72
- 10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT 72

11 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT 73

11.1 OVERVIEW 74
11.2 MEDICATION 76
- 11.2.1 INTEDANIB (OFEV) 77
- 11.2.2 PIRFENIDONE (ESBRIET) 77
11.3 ORGAN TRANSPLANTATION 77
11.4 OXYGEN THERAPY 78
11.5 OTHERS 79

12 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION 80

12.1 OVERVIEW 81
12.2 IDIOPATHIC PULMONARY FIBROSIS 84
12.3 HEPATIC CIRRHOSIS 84
12.4 RENAL FIBROSIS 85
12.5 CUTANEOUS FIBROSIS 86
12.6 OTHERS 87

13 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY END USER 88

13.1 OVERVIEW 89
13.2 HOSPITALS 92
13.3 SPECIALTY CLINICS 93
13.4 ACADEMIC AND RESEARCH INSTITUTES 93
13.5 OTHERS 94

14 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 95

14.1 OVERVIEW 96
14.2 HOSPITAL PHARMACY 99
14.3 RETAIL PHARMACY 99
14.4 OTHERS 100

15 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY REGION 101

15.1 OVERVIEW 102
15.2 NORTH AMERICA 107
- 15.2.1 U.S. 113
- 15.2.2 CANADA 115
- 15.2.3 MEXICO 117
- 15.2.4 DOMINICAN REPUBLIC 119
- 15.2.5 JAMAICA 121
- 15.2.6 PANAMA 123
15.3 EUROPE 125
- 15.3.1 GERMANY 132
- 15.3.2 FRANCE 134
- 15.3.3 U.K. 136
- 15.3.4 ITALY 138
- 15.3.5 SPAIN 140
- 15.3.6 RUSSIA 142
- 15.3.7 TURKEY 144
- 15.3.8 NETHERLANDS 146
- 15.3.9 SWITZERLAND 148
- 15.3.10 HUNGARY 150
- 15.3.11 LITHUANIA 152
- 15.3.12 AUSTRIA 154
- 15.3.13 IRELAND 156
- 15.3.14 NORWAY 158
- 15.3.15 POLAND 160
- 15.3.16 REST OF EUROPE 162
15.4 ASIA-PACIFIC 163
- 15.4.1 JAPAN 170
- 15.4.2 CHINA 172
- 15.4.3 INDIA 174
- 15.4.4 SOUTH KOREA 176
- 15.4.5 AUSTRALIA 178
- 15.4.6 SINGAPORE 180
- 15.4.7 THAILAND 182
- 15.4.8 MALAYSIA 184
- 15.4.9 INDONESIA 186
- 15.4.10 PHILIPPINES 188
- 15.4.11 VIETNAM 190
- 15.4.12 TAIWAN 192
- 15.4.13 REST OF ASIA-PACIFIC 194
15.5 SOUTH AMERICA 195
- 15.5.1 BRAZIL 202
- 15.5.2 ECUADOR 204
- 15.5.3 CHILE 206
- 15.5.4 COLUMBIA 208
- 15.5.5 VENEZUELA 210
- 15.5.6 ARGENTINA 212
- 15.5.7 PERU 214
- 15.5.8 CURACAO 216
- 15.5.9 PARAGUAY 218
- 15.5.10 URUGUAY 220
- 15.5.11 TRINIDAD AND TOBAGO 222
- 15.5.12 REST OF SOUTH AMERICA 224
15.6 MIDDLE EAST AND AFRICA 225
- 15.6.1 SOUTH AFRICA 231
- 15.6.2 SAUDI ARABIA 233
- 15.6.3 U.A.E 235
- 15.6.4 EGYPT 237
- 15.6.5 KUWAIT 239
- 15.6.6 ISRAEL 241
- 15.6.7 BAHRAIN 243
- 15.6.8 REST OF MIDDLE EAST AND AFRICA 245

16 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 246

16.1 COMPANY SHARE ANALYSIS: GLOBAL 246
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 247
16.3 COMPANY SHARE ANALYSIS: EUROPE 248
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 249

17 SWOT ANALYSIS 250

18 COMPANY PROFILE 251

18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 251
- 18.1.1 COMPANY SNAPSHOT 251
- 18.1.2 REVENUE ANALYSIS 251
- 18.1.3 COMPANY SHARE ANALYSIS 252
- 18.1.4 PRODUCT PORTFOLIO 252
- 18.1.5 RECENT DEVELOPMENTS 252
18.2 GENENTECH, INC. 253
- 18.2.1 COMPANY SNAPSHOT 253
- 18.2.2 COMPANY SHARE ANALYSIS 253
- 18.2.3 PRODUCT PORTFOLIO 254
- 18.2.4 RECENT DEVELOPMENTS 254
18.3 SANDOZ INTERNATIONAL GMBH 255
- 18.3.1 COMPANY SNAPSHOT 255
- 18.3.2 COMPANY SHARE ANALYSIS 255
- 18.3.3 PRODUCT PORTFOLIO 256
- 18.3.4 RECENT DEVELOPMENTS 256
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 257
- 18.4.1 COMPANY SNAPSHOT 257
- 18.4.2 REVENUE ANALYSIS 257
- 18.4.3 COMPANY SHARE ANALYSIS 258
- 18.4.4 PRODUCT PORTFOLIO 258
- 18.4.5 RECENT DEVELOPMENTS 258
18.5 ACCORD HEALTHCARE U.S. 259
- 18.5.1 COMPANY SNAPSHOT 259
- 18.5.2 COMPANY SHARE ANALYSIS 259
- 18.5.3 PRODUCT PORTFOLIO 260
- 18.5.4 RECENT DEVELOPMENTS 260
18.6 ABBVIE INC. 261
- 18.6.1 COMPANY SNAPSHOT 261
- 18.6.2 REVENUE ANALYSIS 261
- 18.6.3 PRODUCT PORTFOLIO 262
- 18.6.4 RECENT DEVELOPMENTS 262
18.7 ALPINE IMMUNE SCIENCES 263
- 18.7.1 COMPANY SNAPSHOT 263
- 18.7.2 REVENUE ANALYSIS 263
- 18.7.3 PRODUCT PORTFOLIO 264
- 18.7.4 RECENT DEVELOPMENTS 264
18.8 BELLBROOK LABS 265
- 18.8.1 COMPANY SNAPSHOT 265
- 18.8.2 PRODUCT PORTFOLIO 265
- 18.8.3 RECENT DEVELOPMENTS 265
18.9 BIOMX 266
- 18.9.1 COMPANY SNAPSHOT 266
- 18.9.2 REVENUE ANALYSIS 266
- 18.9.3 PRODUCT PORTFOLIO 267
- 18.9.4 RECENT DEVELOPMENTS 267
18.10 BRISTOL-MYERS SQUIBB COMPANY 268
- 18.10.1 COMPANY SNAPSHOT 268
- 18.10.2 REVENUE ANALYSIS 268
- 18.10.3 PRODUCT PORTFOLIO 269
- 18.10.4 RECENT DEVELOPMENTS 269
18.11 CAMBER PHARMACEUTICALS, INC. 270
- 18.11.1 COMPANY SNAPSHOT 270
- 18.11.2 PRODUCT PORTFOLIO 270
- 18.11.3 RECENT DEVELOPMENTS 270
18.12 ENVEDA 271
- 18.12.1 COMPANY SNAPSHOT 271
- 18.12.2 PRODUCT PORTFOLIO 271
- 18.12.3 RECENT DEVELOPMENTS 271
18.13 GILEAD SCIENCES, INC. 272
- 18.13.1 COMPANY SNAPSHOT 272
- 18.13.2 REVENUE ANALYSIS 272
- 18.13.3 PRODUCT PORTFOLIO 273
- 18.13.4 RECENT DEVELOPMENTS 273
18.14 INTERCEPT PHARMACEUTICALS, INC. 274
- 18.14.1 COMPANY SNAPSHOT 274
- 18.14.2 REVENUE ANALYSIS 274
- 18.14.3 PRODUCT PORTFOLIO 275
- 18.14.4 RECENT DEVELOPMENTS 275
18.15 KITHER BIOTECH S.R.L. 276
- 18.15.1 COMPANY SNAPSHOT 276
- 18.15.2 PRODUCT PORTFOLIO 276
- 18.15.3 RECENT DEVELOPMENTS 276
18.16 PHARMAXIS LTD 277
- 18.16.1 COMPANY SNAPSHOT 277
- 18.16.2 REVENUE ANALYSIS 277
- 18.16.3 PRODUCT PORTFOLIO 278
- 18.16.4 RECENT DEVELOPMENTS 278
18.17 REDX PHARMA PLC. 279
- 18.17.1 COMPANY SNAPSHOT 279
- 18.17.2 REVENUE ANALYSIS 279
- 18.17.3 PRODUCT PORTFOLIO 280
- 18.17.4 RECENT DEVELOPMENTS 280
18.18 VERONA PHARMA PLC 281
- 18.18.1 COMPANY SNAPSHOT 281
- 18.18.2 REVENUE ANALYSIS 281
- 18.18.3 PRODUCT PORTFOLIO 282
- 18.18.4 RECENT DEVELOPMENTS 282

19 QUESTIONNAIRE 283

20 RELATED REPORTS 286

LIST OF TABLES

TABLE 1 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, PIPELINE ANALYSIS 64
TABLE 2 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 76
TABLE 3 GLOBAL MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 77
TABLE 4 GLOBAL MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 77
TABLE 5 GLOBAL ORGAN TRANSPLANTATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 78
TABLE 6 GLOBAL OXYGEN THERAPY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 79
TABLE 7 GLOBAL OTHER IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 79
TABLE 8 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 83
TABLE 9 GLOBAL IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 84
TABLE 10 GLOBAL HEPATIC CIRRHOSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 85
TABLE 11 GLOBAL RENAL FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 86
TABLE 12 GLOBAL CUTANEOUS FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 86
TABLE 13 GLOBAL OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 87
TABLE 14 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 91
TABLE 15 GLOBAL HOSPITALS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 92
TABLE 16 GLOBAL SPECIALTY CLINICS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 93
TABLE 17 GLOBAL ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 94
TABLE 18 GLOBAL OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 94
TABLE 19 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 98
TABLE 20 GLOBAL HOSPITAL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 99
TABLE 21 GLOBAL RETAIL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 100
TABLE 22 GLOBAL OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 100
TABLE 23 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 106
TABLE 24 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 111
TABLE 25 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 111
TABLE 26 NORTH AMERICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 111
TABLE 27 NORTH AMERICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 111
TABLE 28 NORTH AMERICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 112
TABLE 29 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 112
TABLE 30 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 112
TABLE 31 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 112
TABLE 32 U.S. FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 113
TABLE 33 U.S. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 113
TABLE 34 U.S. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 113
TABLE 35 U.S. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 113
TABLE 36 U.S. FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 114
TABLE 37 U.S. FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 114
TABLE 38 U.S. FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 114
TABLE 39 CANADA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 115
TABLE 40 CANADA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 115
TABLE 41 CANADA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 115
TABLE 42 CANADA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 115
TABLE 43 CANADA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 116
TABLE 44 CANADA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 116
TABLE 45 CANADA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 116
TABLE 46 MEXICO FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 117
TABLE 47 MEXICO MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 117
TABLE 48 MEXICO MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 117
TABLE 49 MEXICO MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 117
TABLE 50 MEXICO FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 118
TABLE 51 MEXICO FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 118
TABLE 52 MEXICO FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 118
TABLE 53 DOMINICAN REPUBLIC FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 119
TABLE 54 DOMINICAN REPUBLIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 119
TABLE 55 DOMINICAN REPUBLIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 119
TABLE 56 DOMINICAN REPUBLIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 119
TABLE 57 DOMINICAN REPUBLIC FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 120
TABLE 58 DOMINICAN REPUBLIC FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 120
TABLE 59 DOMINICAN REPUBLIC FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 120
TABLE 60 JAMAICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 121
TABLE 61 JAMAICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 121
TABLE 62 JAMAICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 121
TABLE 63 JAMAICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 121
TABLE 64 JAMAICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 122
TABLE 65 JAMAICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 122
TABLE 66 JAMAICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 122
TABLE 67 PANAMA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 123
TABLE 68 PANAMA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 123
TABLE 69 PANAMA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 123
TABLE 70 PANAMA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 123
TABLE 71 PANAMA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 124
TABLE 72 PANAMA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 124
TABLE 73 PANAMA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 124
TABLE 74 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 129
TABLE 75 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 129
TABLE 76 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 129
TABLE 77 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 130
TABLE 78 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 130
TABLE 79 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 130
TABLE 80 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 130
TABLE 81 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 131
TABLE 82 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 132
TABLE 83 GERMANY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 132
TABLE 84 GERMANY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 132
TABLE 85 GERMANY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 132
TABLE 86 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 133
TABLE 87 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 133
TABLE 88 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 133
TABLE 89 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 134
TABLE 90 FRANCE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 134
TABLE 91 FRANCE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 134
TABLE 92 FRANCE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 134
TABLE 93 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 135
TABLE 94 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 135
TABLE 95 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 135
TABLE 96 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 136
TABLE 97 U.K. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 136
TABLE 98 U.K. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 136
TABLE 99 U.K. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 136
TABLE 100 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 137
TABLE 101 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 137
TABLE 102 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 137
TABLE 103 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 138
TABLE 104 ITALY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 138
TABLE 105 ITALY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 138
TABLE 106 ITALY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 138
TABLE 107 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 139
TABLE 108 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 139
TABLE 109 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 139
TABLE 110 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 140
TABLE 111 SPAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 140
TABLE 112 SPAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 140
TABLE 113 SPAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 140
TABLE 114 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 141
TABLE 115 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 141
TABLE 116 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 141
TABLE 117 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 142
TABLE 118 RUSSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 142
TABLE 119 RUSSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 142
TABLE 120 RUSSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 142
TABLE 121 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 143
TABLE 122 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 143
TABLE 123 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 143
TABLE 124 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 144
TABLE 125 TURKEY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 144
TABLE 126 TURKEY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 144
TABLE 127 TURKEY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 144
TABLE 128 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 145
TABLE 129 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 145
TABLE 130 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 145
TABLE 131 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 146
TABLE 132 NETHERLANDS MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 146
TABLE 133 NETHERLANDS MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 146
TABLE 134 NETHERLANDS MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 146
TABLE 135 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 147
TABLE 136 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 147
TABLE 137 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 147
TABLE 138 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 148
TABLE 139 SWITZERLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 148
TABLE 140 SWITZERLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 148
TABLE 141 SWITZERLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 148
TABLE 142 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 149
TABLE 143 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 149
TABLE 144 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 149
TABLE 145 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 150
TABLE 146 HUNGARY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 150
TABLE 147 HUNGARY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 150
TABLE 148 HUNGARY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 150
TABLE 149 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 151
TABLE 150 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 151
TABLE 151 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 151
TABLE 152 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 152
TABLE 153 LITHUANIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 152
TABLE 154 LITHUANIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 152
TABLE 155 LITHUANIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 152
TABLE 156 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 153
TABLE 157 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 153
TABLE 158 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 153
TABLE 159 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 154
TABLE 160 AUSTRIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 154
TABLE 161 AUSTRIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 154
TABLE 162 AUSTRIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 154
TABLE 163 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 155
TABLE 164 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 155
TABLE 165 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 155
TABLE 166 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 156
TABLE 167 IRELAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 156
TABLE 168 IRELAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 156
TABLE 169 IRELAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 156
TABLE 170 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 157
TABLE 171 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 157
TABLE 172 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 157
TABLE 173 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 158
TABLE 174 NORWAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 158
TABLE 175 NORWAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 158
TABLE 176 NORWAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 158
TABLE 177 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 159
TABLE 178 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 159
TABLE 179 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 159
TABLE 180 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 160
TABLE 181 POLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 160
TABLE 182 POLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 160
TABLE 183 POLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 160
TABLE 184 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 161
TABLE 185 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 161
TABLE 186 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 161
TABLE 187 REST OF EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 162
TABLE 188 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 167
TABLE 189 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 167
TABLE 190 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 168
TABLE 191 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 168
TABLE 192 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 168
TABLE 193 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 168
TABLE 194 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 169
TABLE 195 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 169
TABLE 196 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 170
TABLE 197 JAPAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 170
TABLE 198 JAPAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 170
TABLE 199 JAPAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 170
TABLE 200 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 171
TABLE 201 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 171
TABLE 202 JAPAN FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 171
TABLE 203 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 172
TABLE 204 CHINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 172
TABLE 205 CHINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 172
TABLE 206 CHINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 172
TABLE 207 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 173
TABLE 208 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 173
TABLE 209 CHINA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 173
TABLE 210 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 174
TABLE 211 INDIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 174
TABLE 212 INDIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 174
TABLE 213 INDIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 174
TABLE 214 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 175
TABLE 215 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 175
TABLE 216 INDIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 175

TABLE 217 SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 176
TABLE 218 SOUTH KOREA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 176
TABLE 219 SOUTH KOREA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 176
TABLE 220 SOUTH KOREA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 176
TABLE 221 SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 177
TABLE 222 SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 177
TABLE 223 SOUTH KOREA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 177
TABLE 224 AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 178
TABLE 225 AUSTRALIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 178
TABLE 226 AUSTRALIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 178
TABLE 227 AUSTRALIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 178
TABLE 228 AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 179
TABLE 229 AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 179
TABLE 230 AUSTRALIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 179
TABLE 231 SINGAPORE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 180
TABLE 232 SINGAPORE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 180
TABLE 233 SINGAPORE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 180
TABLE 234 SINGAPORE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 180
TABLE 235 SINGAPORE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 181
TABLE 236 SINGAPORE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 181
TABLE 237 SINGAPORE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 181
TABLE 238 THAILAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 182
TABLE 239 THAILAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 182
TABLE 240 THAILAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 182
TABLE 241 THAILAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 182
TABLE 242 THAILAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 183
TABLE 243 THAILAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 183
TABLE 244 THAILAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 183
TABLE 245 MALAYSIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 184
TABLE 246 MALAYSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 184
TABLE 247 MALAYSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 184
TABLE 248 MALAYSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 184
TABLE 249 MALAYSIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 185
TABLE 250 MALAYSIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 185
TABLE 251 MALAYSIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 185
TABLE 252 INDONESIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 186
TABLE 253 INDONESIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 186
TABLE 254 INDONESIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 186
TABLE 255 INDONESIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 186
TABLE 256 INDONESIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 187
TABLE 257 INDONESIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 187
TABLE 258 INDONESIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 187
TABLE 259 PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 188
TABLE 260 PHILIPPINES MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 188
TABLE 261 PHILIPPINES MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 188
TABLE 262 PHILIPPINES MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 188
TABLE 263 PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 189
TABLE 264 PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 189
TABLE 265 PHILIPPINES FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 189
TABLE 266 VIETNAM FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 190
TABLE 267 VIETNAM MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 190
TABLE 268 VIETNAM MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 190
TABLE 269 VIETNAM MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 190
TABLE 270 VIETNAM FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 191
TABLE 271 VIETNAM FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 191
TABLE 272 VIETNAM FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 191
TABLE 273 TAIWAN FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 192
TABLE 274 TAIWAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 192
TABLE 275 TAIWAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 192
TABLE 276 TAIWAN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 192
TABLE 277 TAIWAN FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 193
TABLE 278 TAIWAN FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 193
TABLE 279 TAIWAN FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 193
TABLE 280 REST OF ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 194
TABLE 281 SOUTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 199
TABLE 282 SOUTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 199
TABLE 283 SOUTH AMERICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 199
TABLE 284 SOUTH AMERICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 200
TABLE 285 SOUTH AMERICA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 200
TABLE 286 SOUTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 200
TABLE 287 SOUTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 200
TABLE 288 SOUTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 201
TABLE 289 BRAZIL FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 202
TABLE 290 BRAZIL MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 202
TABLE 291 BRAZIL MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 202
TABLE 292 BRAZIL MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 202
TABLE 293 BRAZIL FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 203
TABLE 294 BRAZIL FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 203
TABLE 295 BRAZIL FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 203
TABLE 296 ECUADOR FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 204
TABLE 297 ECUADOR MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 204
TABLE 298 ECUADOR MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 204
TABLE 299 ECUADOR MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 204
TABLE 300 ECUADOR FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 205
TABLE 301 ECUADOR FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 205
TABLE 302 ECUADOR FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 205
TABLE 303 CHILE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 206
TABLE 304 CHILE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 206
TABLE 305 CHILE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 206
TABLE 306 CHILE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 206
TABLE 307 CHILE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 207
TABLE 308 CHILE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 207
TABLE 309 CHILE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 207
TABLE 310 COLUMBIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 208
TABLE 311 COLUMBIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 208
TABLE 312 COLUMBIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 208
TABLE 313 COLUMBIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 208
TABLE 314 COLUMBIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 209
TABLE 315 COLUMBIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 209
TABLE 316 COLUMBIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 209
TABLE 317 VENEZUELA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 210
TABLE 318 VENEZUELA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 210
TABLE 319 VENEZUELA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 210
TABLE 320 VENEZUELA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 210
TABLE 321 VENEZUELA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 211
TABLE 322 VENEZUELA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 211
TABLE 323 VENEZUELA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 211
TABLE 324 ARGENTINA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 212
TABLE 325 ARGENTINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 212
TABLE 326 ARGENTINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 212
TABLE 327 ARGENTINA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 212
TABLE 328 ARGENTINA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 213
TABLE 329 ARGENTINA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 213
TABLE 330 ARGENTINA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 213
TABLE 331 PERU FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 214
TABLE 332 PERU MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 214
TABLE 333 PERU MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 214
TABLE 334 PERU MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 214
TABLE 335 PERU FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 215
TABLE 336 PERU FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 215
TABLE 337 PERU FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 215
TABLE 338 CURACAO FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 216
TABLE 339 CURACAO MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 216
TABLE 340 CURACAO MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 216
TABLE 341 CURACAO MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 216
TABLE 342 CURACAO FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 217
TABLE 343 CURACAO FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 217
TABLE 344 CURACAO FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 217
TABLE 345 PARAGUAY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 218
TABLE 346 PARAGUAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 218
TABLE 347 PARAGUAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 218
TABLE 348 PARAGUAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 218
TABLE 349 PARAGUAY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 219
TABLE 350 PARAGUAY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 219
TABLE 351 PARAGUAY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 219
TABLE 352 URUGUAY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 220
TABLE 353 URUGUAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 220
TABLE 354 URUGUAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 220
TABLE 355 URUGUAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 220
TABLE 356 URUGUAY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 221
TABLE 357 URUGUAY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 221
TABLE 358 URUGUAY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 221
TABLE 359 TRINIDAD AND TOBAGO FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 222
TABLE 360 TRINIDAD AND TOBAGO MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 222
TABLE 361 TRINIDAD AND TOBAGO MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 222
TABLE 362 TRINIDAD AND TOBAGO MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 222
TABLE 363 TRINIDAD AND TOBAGO FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 223
TABLE 364 TRINIDAD AND TOBAGO FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 223
TABLE 365 TRINIDAD AND TOBAGO FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 223
TABLE 366 REST OF SOUTH AMERICA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 224

LIST OF FIGURES

FIGURE 1 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: SEGMENTATION 38
FIGURE 2 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: DATA TRIANGULATION 41
FIGURE 3 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: DROC ANALYSIS 42
FIGURE 4 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS 43
FIGURE 5 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 43
FIGURE 6 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 45
FIGURE 7 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: DBMR MARKET POSITION GRID 46
FIGURE 8 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: MARKET END USER COVERAGE GRID 47
FIGURE 9 GLOBAL FIBROTIC DISEASES TREATMENT MARKET : VENDOR SHARE ANALYSIS 48
FIGURE 10 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: SEGMENTATION 51
FIGURE 11 RISING PREVALENCE OF FIBROTIC DISEASES IS EXPECTED TO DRIVE THE GLOBAL FIBROTIC DISEASES TREATMENT MARKET GROWTH IN THE FORECAST PERIOD 52
FIGURE 12 MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL FIBROTIC DISEASES TREATMENT MARKET IN 2023 & 2030 52
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL FIBROTIC DISEASES TREATMENT MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD 53
FIGURE 14 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR GLOBAL FIBROTIC DISEASES TREATMENT MARKET MANUFACTURERS IN THE FORECAST PERIOD 54
FIGURE 15 PATIENT FLOW DIAGRAM 62
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE GLOBAL FIBROTIC DISEASES TREATMENT MARKET 68
FIGURE 17 GLOBAL FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT 2022 74
FIGURE 18 GLOBAL FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT 2023-2030 (USD THOUSAND) 75
FIGURE 19 GLOBAL FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT CAGR (2023-2030) 75
FIGURE 20 GLOBAL FIBROTIC DISEASES TREATMENT MARKET BY TREATMENT LIFELINE CURVE 76
FIGURE 21 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, 2022 81
FIGURE 22 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, 2023-2030 (USD THOUSAND) 82
FIGURE 23 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, CAGR (2023-2030) 82
FIGURE 24 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY APPLICATION, LIFELINE CURVE 83
FIGURE 25 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY END USER, 2022 89
FIGURE 26 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 90
FIGURE 27 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY END USER, CAGR (2023-2030) 90
FIGURE 28 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY END USER, LIFELINE CURVE 91
FIGURE 29 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 96
FIGURE 30 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 97
FIGURE 31 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030) 97
FIGURE 32 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 98
FIGURE 33 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: SNAPSHOT (2022) 103
FIGURE 34 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY REGION (2022) 104
FIGURE 35 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY REGION (2023 & 2030) 104
FIGURE 36 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY REGION (2022 & 2030) 105
FIGURE 37 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT (2023-2030) 105
FIGURE 38 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: SNAPSHOT (2022) 108
FIGURE 39 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022) 109
FIGURE 40 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2023 & 2030) 109
FIGURE 41 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022 & 2030) 110
FIGURE 42 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: TREATMENT (2023-2030) 110
FIGURE 43 EUROPE FIBROTIC DISEASES TREATMENT MARKET: SNAPSHOT (2022) 126
FIGURE 44 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022) 127
FIGURE 45 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2023 & 2030) 127
FIGURE 46 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022 & 2030) 128
FIGURE 47 EUROPE FIBROTIC DISEASES TREATMENT MARKET: TREATMENT (2023-2030) 128
FIGURE 48 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET: SNAPSHOT (2022) 164
FIGURE 49 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022) 165
FIGURE 50 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2023 & 2030) 165
FIGURE 51 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022 & 2030) 166
FIGURE 52 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET: TREATMENT (2023-2030) 166
FIGURE 53 SOUTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: SNAPSHOT (2022) 196
FIGURE 54 SOUTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022) 197
FIGURE 55 SOUTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2023 & 2030) 197
FIGURE 56 SOUTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022 & 2030) 198
FIGURE 57 SOUTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: TREATMENT (2023-2030) 198
FIGURE 58 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET: SNAPSHOT (2022) 226
FIGURE 59 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022) 227
FIGURE 60 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2023 & 2030) 227
FIGURE 61 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET: BY COUNTRY (2022 & 2030) 228
FIGURE 62 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET: TREATMENT (2023-2030) 228
FIGURE 63 GLOBAL FIBROTIC DISEASES TREATMENT MARKET: COMPANY SHARE 2022 (%) 246
FIGURE 64 NORTH AMERICA FIBROTIC DISEASES TREATMENT MARKET: COMPANY SHARE 2022 (%) 247
FIGURE 65 EUROPE FIBROTIC DISEASES TREATMENT MARKET: COMPANY SHARE 2022 (%) 248
FIGURE 66 ASIA-PACIFIC FIBROTIC DISEASES TREATMENT MARKET: COMPANY SHARE 2022 (%) 249